| Hemophilia A
Afstyla vs Hympavzi
Side-by-side clinical, coverage, and cost comparison for hemophilia a.Deep comparison between: Afstyla vs Hympavzi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsHympavzi has a higher rate of injection site reactions vs Afstyla based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Hympavzi but not Afstyla, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Afstyla
Hympavzi
At A Glance
IV infusion
2-3 times weekly
Recombinant Factor VIII
SC injection
Weekly
TFPI antagonist
Indications
- Hemophilia A
- Hemophilia A
- Hemophilia B
Dosing
Hemophilia A - On-demand treatment and control of bleeding Target Factor VIII activity 20-40 IU/dL for minor bleeds, 30-60 IU/dL for moderate bleeds, and 60-100 IU/dL for major/life-threatening bleeds; repeat IV injection every 8-24 hours until bleeding is resolved. Dose (IU) = body weight (kg) x desired Factor VIII rise (IU/dL) x 0.5.
Hemophilia A - Routine prophylaxis Adults and adolescents (>=12 years): 20-50 IU/kg IV 2-3 times weekly; children may require more frequent dosing based on pharmacokinetic data and individual response.
Hemophilia A - Perioperative management Target 30-60 IU/dL for minor surgery (repeat every 24 hours for >=1 day); target 80-100 IU/dL for major surgery (repeat every 8-24 hours until adequate wound healing, then maintain 30-60 IU/dL for >=7 more days) via IV injection.
Hemophilia A, Hemophilia B Loading dose 300 mg SC (two 150 mg injections); maintenance 150 mg SC once weekly starting one week after loading dose; consider dose adjustment to 300 mg SC weekly in patients >=50 kg with inadequate bleeding control.
Contraindications
- Life-threatening hypersensitivity reactions, including anaphylaxis, to AFSTYLA or any excipient (e.g., polysorbate 80) or to hamster proteins
—
Adverse Reactions
Most common (>0.5%) Factor VIII inhibition (in previously untreated patients), hypersensitivity, dizziness
Postmarketing Factor VIII inhibitor development
Most common (>=3%) Injection site reaction, headache, pruritus
Serious Thromboembolic events, hypersensitivity, peripheral swelling, venous thrombosis
Pharmacology
AFSTYLA is a recombinant single-chain Factor VIII with a truncated B-domain and covalent linkage between heavy and light chains that replaces missing Coagulation Factor VIII needed for effective hemostasis; it exhibits higher VWF affinity relative to full-length rFVIII, providing increased molecular stability and protection from degradation.
Marstacimab-hncq is a human monoclonal IgG1 antibody that targets the Kunitz domain 2 (K2) of tissue factor pathway inhibitor (TFPI), neutralizing TFPI activity and enhancing thrombin generation via the extrinsic coagulation pathway.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Afstyla
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Hympavzi
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Afstyla
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Hympavzi
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (3/8)
Humana
Afstyla
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Hympavzi
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Inherited and Acquired Factor Deficiencies - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Inherited and Acquired Factor Deficiencies - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AfstylaView full Afstyla profile
HympavziView full Hympavzi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.